Who
Kameel D. Farag
Interim CFO
Company insider
Files Form 4 as: Interim CFO, Akari Therapeutics; Director, BioVie.
In numbers
- Trades disclosed
- 25
- Buys
- 0
- Sells
- 0
- Bought
- $0
- Sold
- $0
- Companies
- 2
- Companies where not an officer
- 1
- First trade
- 22 Oct 2025
- Last trade
- 17 Aug 2026
- Last filed
- 19 Aug 2026
Companies traded
Activity over time
Not enough dated trades to draw.
Every trade
| Traded | Company | What | Amount | |
|---|---|---|---|---|
| 17 Aug 2026filed 19 Aug 2026 | AKTX Akari TherapeuticsBiotechnology | SEC FORM 4 Code A | $13K1,728 at $7.52 | filing |
| 17 Aug 2026filed 19 Aug 2026 | AKTX Akari TherapeuticsBiotechnology | SEC FORM 4 Code A | $13K1,728 at $7.52 | filing |
| 16 Jul 2026filed 5 Aug 2026 | AKTX Akari TherapeuticsBiotechnology | SEC FORM 4 Code A | $13K1,130 at $11.50 | filing |
| 16 Jul 2026filed 5 Aug 2026 | AKTX Akari TherapeuticsBiotechnology | SEC FORM 4 Code A | $13K1,130 at $11.50 | filing |
| 24 Jun 2026filed 25 Jun 2026 | AKTX Akari TherapeuticsBiotechnology | SEC FORM 4 Code A | $13K1,248 at $10.02 | filing |
| 24 Jun 2026filed 25 Jun 2026 | AKTX Akari TherapeuticsBiotechnology | SEC FORM 4 Code A | $13K1,395 at $9.32 | filing |
| 24 Jun 2026filed 25 Jun 2026 | AKTX Akari TherapeuticsBiotechnology | SEC FORM 4 Code A | $13K1,570 at $8.28 | filing |
| 24 Jun 2026filed 25 Jun 2026 | AKTX Akari TherapeuticsBiotechnology | SEC FORM 4 Code A | $13K2,539 at $5.12 | filing |
| 24 Jun 2026filed 25 Jun 2026 | AKTX Akari TherapeuticsBiotechnology | SEC FORM 4 Code A | $13K3,725 at $3.49 | filing |
| 24 Jun 2026filed 25 Jun 2026 | AKTX Akari TherapeuticsBiotechnology | SEC FORM 4 Code A | $28K7,353 at $3.74 | filing |
| 24 Jun 2026filed 25 Jun 2026 | AKTX Akari TherapeuticsBiotechnology | SEC FORM 4 Code A | $13K1,000 at $13.00 | filing |
| 24 Jun 2026filed 25 Jun 2026 | AKTX Akari TherapeuticsBiotechnology | SEC FORM 4 Code A | $13K1,248 at $10.02 | filing |
| 24 Jun 2026filed 25 Jun 2026 | AKTX Akari TherapeuticsBiotechnology | SEC FORM 4 Code A | $13K1,395 at $9.32 | filing |
| 24 Jun 2026filed 25 Jun 2026 | AKTX Akari TherapeuticsBiotechnology | SEC FORM 4 Code A | $13K1,570 at $8.28 | filing |
| 24 Jun 2026filed 25 Jun 2026 | AKTX Akari TherapeuticsBiotechnology | SEC FORM 4 Code A | $13K2,539 at $5.12 | filing |
| 24 Jun 2026filed 25 Jun 2026 | AKTX Akari TherapeuticsBiotechnology | SEC FORM 4 Code A | $13K3,725 at $3.49 | filing |
| 24 Jun 2026filed 25 Jun 2026 | AKTX Akari TherapeuticsBiotechnology | SEC FORM 4 Code A | $28K7,353 at $3.74 | filing |
| 24 Jun 2026filed 25 Jun 2026 | AKTX Akari TherapeuticsBiotechnology | SEC FORM 4 Code A | $13K1,000 at $13.00 | filing |
| 5 Jan 2026filed 9 Jan 2026 | BIVI BioVieoption or derivative · Biotechnology | SEC FORM 4 Code A | —57,500 at $0.00 | filing |
| 5 Jan 2026filed 9 Jan 2026 | BIVI BioVieoption or derivative · Biotechnology | SEC FORM 4 Code A | —57,500 at $0.00 | filing |
News
No headline names them, or the companies they trade most, lately.
Sectors
No trade we could place in a sector.